Xu et al. (2019) developed HA-NPs-PTC209, a colon cancer-targeted system to deliver the BMI-1 inhibitor, PTC209. PTC209 reverses stemness of CRC, thus reducing recurrence and metastasis of CRC. These HA-modified NPs have high affinity to CRC cells with high expression of CD44/CD168, and show effective targeting of tumor site. In addition, HA-CPT/CUR-NPs is a HA-modified NP developed by loading camptothecin (CPT)/curcumin (CUR) with HA-functionalized polymeric NPs (Xiao et al., 2015). This evidence concerns the gene CD44 and colorectal carcinoma.